In 2024 and as of 30 of April, approximately 240 000 CHIKVD cases and over 90 deaths have been reported worldwide. A total of 18 countries reported CHIKVD cases from the Americas (11), Asia (6), and Africa (1).
This list below shows the current accommodation sites in EU/EEA countries with which clusters of Legionnaires’ disease have been identified but where the European Legionnaires’ disease Surveillance Network (ELDSNet) is unable to assess the risk of Legionella infection, or where ELDSNet believe there may be increased risk to travellers.
In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.